SHR0302 tablets、Placebo

Phase 3

JJiangsu HengRui Medicine Co., Ltd.

SHR0302 tablets、Placebo is one of 35 therapeutic programs targeting Psoriatic Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Psoriatic ArthritisActive, not recruiting

Psoriatic ArthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Psoriatic Arthritis

#DrugCompanyPhaseTrials

Otezla

Amgen

Approved

18 2

Trexall

Jazz Pharmaceuticals

Approved

13 3

Bimzelx

UCB

Approved

9 4

Taltz

Eli Lilly

Approved

8 5

Rinvoq

AbbVie

Approved

4 6

Mounjaro

Eli Lilly

Approved

3 7

Arava

Sanofi

Approved

2 8

Azulfidine

Pfizer

Approved

2 9

Ozempic

Novo Nordisk

Approved

1 10

Medrol

Pfizer

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Psoriatic Arthritis

NCT04957550

Clinical

Trials by Indication[1]

Psoriatic Arthritis1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Psoriatic Arthritis Subjects

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04957550·418 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHR0302 tablets、Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for SHR0302 tablets、Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

SHR0302 tablets、Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Psoriatic Arthritis1 trial

References

Drug Info

Quick Facts

Related News